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Background/Objectives: The application of lactic acid bacteria (LAB) and biﬁdobacteria, which exhibit
therapeutic beneﬁts, in dermatology, including treatment of skin infections speciﬁcally caused by
Staphylococcus aureus, is new. The objectives of this study were to screen LAB and biﬁdobacteria for
antimicrobial activity against S. aureus and to identify the antimicrobial compounds produced by LAB. In
addition, the study aimed to inhibit the bioﬁlm of S. aureus with extracellular extracts of LAB.
Methods: A total of 87 strains of LAB and three strains of biﬁdobacteria, grouped according to their
respective origins, were screened for antimicrobial activity against S. aureus using the cell-free super-
natant (CFS). Antimicrobial activity of the CFS was evaluated following neutralization, protease treat-
ment, and protein precipitation treatment. Characterization was performed to identify the antimicrobial
compounds in the CFS. Inhibition of the S. aureus bioﬁlm was assessed with a crystal violet assay.
Results: LAB and biﬁdobacteria inhibited the growth of S. aureus, with percentage of growth inhibition
ranging from 0.5% to 34.2%. All strains demonstrated a drastic reduction (p < 0.05) in growth inhibition
upon neutralization. Antimicrobial compounds in the CFS were lactic acid, acetic acid, hydrogen
peroxide, and diacetyl. The CFS of strain Lactobacillus bulgaricus FTDC 8611 signiﬁcantly hindered
(p < 0.05) the bioﬁlm formation of S. aureus. Statistical analysis was performed with SPSS version 19.0.
Conclusion: LAB were able to produce antimicrobial compounds that inhibit S. aureus. The inhibitory
action of the CFS was mainly due to the organic acids produced by LAB. Antimicrobial metabolites
produced by LAB comprise lactic acid, acetic acid, hydrogen peroxide, and diacetyl. S. aureus was able to
form a bioﬁlm, which was successfully inhibited by the CFS of L. bulgaricus FTDC 8611.
Copyright  2014, Taiwanese Dermatological Association.
Published by Elsevier Taiwan LLC. All rights reserved.Introduction
In the recent years, various therapeutic beneﬁts of lactic acid bac-
teria (LAB) and biﬁdobacteria have been studied extensively, but
their application in dermatology remains new. Staphylococcus
aureus is Gram-positive cocci that have been identiﬁed to be most
virulent among all staphylococcal species to cause skin and soft
tissue infections, surgical site infections, and hospital-acquired
bloodstream infections.1 In some infections, survival, dissemina-
tion, and pathogenesis of staphylococci are supported by the for-
mation of a bioﬁlm.2 Treating infections in which bioﬁlms arey have no ﬁnancial or non-
tter or materials discussed in
echnology, Universiti Sains
).
cal Association. Published by Elsevinvolved is very difﬁcult, and due to the emergence of methicillin-
resistant S. aureus, alternative natural antibacterial therapies have
gained much attention.3,4
LAB and biﬁdobacteria are useful for a variety of applications due
to their therapeutic effects; these microorganisms are, in general,
nonpathogenic, and thus have been assigned a “generally recognized
as safe” status.5 These microorganisms have been highlighted for
their ability to treat acute infectious diarrhea, antibiotic-associated
diarrhea, viral infections of the respiratory tract, inﬂammatory
bowel disease, and cholesterol lowering.6 In recent studies, beneﬁcial
effects of LAB and biﬁdobacteria that extend beyond the gut were
uncovered, as these bacteria also demonstrated their potential in
promoting dermal health and exerting cellular immunity response
required for in skin defence.7 Bioactive compounds that were found
to be useful in dermatological applications included hyaluronic acid,
peptidoglycan, lipoteichoic acid, and sphingomyelinase. These com-
poundswere produced by LAB at an effective concentration to inhibit
pathogens causing dermal illness.7ier Taiwan LLC. All rights reserved.
Table 1 Origin of lactic acid bacterial strain.
Category No. Source/origin Strain
Dairy A1 Cow milk Lactobacillus acidophilus
FTDC 2333
A2 Cow milk L. acidophilus FTDC 2131
A3 Cow milk Biﬁdobacterium FTDC 2142
A4 Cow milk L. acidophilus FTDC 2133
A5 Cow milk Lactobacillus FTDC 2113
A6 Cow milk L. acidophilus FTDC 1231
A7 Cow milk L. acidophilus FTDC 1733
A8 Cow milk Lactobacillus bulgaricus
FTDC 1311
A9 Cow milk L. bulgaricus FTDC 1511
A10 Cow milk Lactobacillus brevis
BD 1312b
A11 Cow milk Lactobacillus fermentum
BD 1312
A12 Cow milk Lactobacillus casei
BD 1313a
A13 Cow milk Lactobacillus plantarum
BD 8313b
A14 Cow milk L. plantarum BD 8313c
A15 Yogurt L. fermentum BD 8312b
A16 Cow milk L. casei BD 1313b
A17 Cow milk L. fermentum BD 8313a
A18 Yogurt L. fermentum BD 8311
A19 Cow milk L. fermentum BD 8315
A20 Yogurt L. fermentum BD 8312a
A21 Cow milk Biﬁdobacterium longum
FTDC 8843
A22 Cow milk L. acidophilus FTDC 8033
A23 Cow milk L. bulgaricus FTDC 8011
A24 Cow milk L. acidophilus FTDC 8833
A25 Cow milk Biﬁdobacterium FTDC 8943
A26 Cow milk L. acidophilus FTDC 8933
A27 Cow milk L. bulgaricus FTDC 8913
A28 Cow milk Weissella cibaria
FTDC 8643
A29 Cow milk Lactobacillus. gasseri
FTDC 8131
A30 Cow milk L. bulgaricus FTDC 8611
A31 Cow milk L. bulgaricus FTCC 0411
A32 Cow Milk L. casei FTCC 0442
A33 Cow Milk L. acidophilus FTCC 0291
Vegetable B1 Old cucumber L. brevis BD 1515
B2 Tomato Lactobacillus paracasei
BD 1512e
B3 Tomato L. plantarum BD 1512f
B4 Cabbage W. cibaria BD 1512i
B5 Cabbage L. fermentum BD 1512j
B6 Butterhead L. casei BD 1513f
B7 Butterhead W. cibaria BD 1514h
B8 Cabbage W. cibaria BD 8513b
B9 Spinach L. fermentum BD 1512k
B10 Spinach W. cibaria BD 8513j
B11 Spinach Weissella confusa
BD 8513k
B12 Tomato L. fermentum BD 8515a
B13 Purple cabbage L. casei BD 8513g
B14 Purple cabbage L. fermentum BD 8513h
Fruits C1 Water chestnut L. casei BD 1512a
C2 Ciku L. casei BD 1512b
C3 Guava L. casei BD 1512d
C4 Dukung L. brevis BD 1512m
C5 Pineapple L. fermentum BD 1512n
C6 Water chestnut L. brevis BD 1513a
C7 Dukung L. casei BD 1513c
C8 Kiwi L. fermentum BD 8513d
C9 Kiwi L. plantarum BD 8513e
C10 Kiwi L. plantarum BD 8513f
C11 Mango L. fermentum BD 8513r
C12 Mango L. fermentum BD 8513q
C13 Pineapple L. fermentum BD 8513a
Meat D1 German sausage L. paracasei BD 1611a
D2 German sausage L. casei BD 1611c
D3 Pork minced meat L. plantarum BD 8613c
D4 BBQ pork sausage L. plantarum BD 8913b
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gest that the therapeutic effects exhibited by these microorganisms
are due to the secretion of various inhibitory compounds, particu-
larly LAB, which can produce growth-inhibitive compounds such as
lactic acid, acetic acid, bacteriocin, hydrogen peroxide, and diace-
tyl.7e9 The unique ability of LAB and biﬁdobacteria to produce
organic acids not only empower bacteria with the ability to pre-
serve food, but also to inhibit pathogenic microorganisms by
penetrating the targeted bacterial membranes and interfering with
the essential metabolic functions.9,10 Bacteriocins are another
group of interesting natural antimicrobial compounds produced by
LAB, which resemble antibiotics; they work by adhering to speciﬁc
receptors on targeted bacterial cytoplasmic membrane and affect
the metabolic activity within cells.11
Such evidence of therapeutic effects suggested that LAB and
biﬁdobacteria could be used for inhibiting the growth as well as
eradicating the bioﬁlm of dermatological pathogen S. aureus. Thus,
the aim of this study is to evaluate the antimicrobial activity of LAB
and biﬁdobacteria, as well as the antimicrobial compounds pro-
duced in theextracellularextractsof thesebacteria, against S. aureus.
Methods
Bacteria strains and media
A total of 87 strains of LAB and three strains of biﬁdobacteria and
S. aureus were obtained from the Culture Collection Centre of Bio-
process Technology Division, School of Industrial Technology,
Universiti Sains Malaysia (Penang, Malaysia). The LAB strains used
in this study are listed in Table 1. De ManeRogosaeSharpe (MRS)
broth (Biomark, Pune, India) was used for the incubation of LAB and
biﬁdobacteria strains. LAB and biﬁdobacteria strains were activated
using 10% (v/v) inoculum in MRS broth at 37C for 24 hours under
static conditions and were subcultured twice prior to use. These
LAB and biﬁdobacteria strains were used as antimicrobial com-
pounds producing strain. The pathogen S. aureus was activated in
sterile tryptic soy broth (TSB) (Biomark) with 10% inoculum at 37C
for 24 hours. It was subcultured twice in TSB prior to use. All bac-
teria strains were preserved at 20C in 40% glycerol.12
Screening for antimicrobial activity
Activated LAB and biﬁdobacteria strains were incubated in MRS
broth for 20 hours at 37C and standardized to an optical density
(600 nm) of 1.000  0.05 upon incubation. Cell cultures were
centrifuged at 1100  g for 10 minutes; next, the supernatants
(extracellular extracts) were collected and subsequently ﬁlter
sterilized. The resulting ﬁltrates were designated as crude cell-free
supernatant (CCFS). Each 100 mL of CCFS weighed 103 mg. The assay
was carried out in 96-well microplates.13 Activated S. aureus was
grown in TSB at 37C for 20 hours and standardized to an optical
density (600 nm) of 0.300  0.015. A total of 100 mL S. aureus cell
suspension and 100 mL LAB CCFS were added to the 96-well
microplate and incubated at 37C for 20 hours. Turbidity was
measured as the absorbance at 596 nm. A negative control was
prepared using MRS broth to replace the LAB extracts. A positive
control was prepared with streptomycin (10 mg/mL) to replace the
LAB extracts. The percentage of growth inhibition was calculated
based on the following equation14:
% I ¼ OD control OD sample
OD control
 100 [1]
where I (%) is the percentage of inhibition of the sample in relation
to the growth control, OD control represents the changes in the
Table 1 (continued )
Category No. Source/origin Strain
D5 Cheesy pork sausage L. fermentum BD 8913d
D6 Pork minced meat L. fermentum BD 8613b
D7 BBQ pork sausage L. fermentum BD 8913a
D8 Chinese sausage L. plantarum BD 8913c
D9 Cheesy pork sausage L. fermentum BD 8913e
D10 Cheesy pork sausage L. fermentum BD 8913f
D11 Beef sausage W. confuse BD 8913k
D12 Beef sausage L. fermentum BD 8913l
D13 Chinese sausage Lactococcus gravieae
BD 8914d
Fermented
food products
E1 Sourdough L. paracasei BD 1415a
E2 Sourdough L. casei BD 1415b
E3 Coconut milk L. brevis BD 1512g
E4 Coconut milk L. brevis BD 1512h
E5 Tosai L. brevis BD 1912c
E6 Kimchi L. fermentum BD 1913a
E7 Tempoyak Pediococcus pentosaceus
BD 1913b
E8 Fermented bean curd L. fermentum BD 8912
E9 Sourdough L. fermentum BD 1415c
E10 Beancurd L. casei BD 1511a
E11 Tosai L. casei BD 1912b
E12 Pickle mustard L. fermentum BD 1912d
E13 Fermented olives L. fermentum BD 8513c
E14 Octopus L. fermentum BD 8613d
E15 Tosai Lactobacillus delbrueckii
subsp. bulgaricus BD 8913i
E16 Tosai L. plantarum BD 8913g
E17 Pickled cucumber Leuconostoc. mesenteroides
BD 8914a
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changes in the optical density of the sample.
Determination of pH
Activated cultures of LAB were incubated in MRS broth at 37C for
20 hours. The pH of bacterial cultures prior to and after fermen-
tation was measured with a pH meter equipped with an automatic
temperature compensation probe (CyberScan pH 510, EUTECH,
Singapore).
Antimicrobial activity of neutralized CCFS
The pH of LAB supernatants (OD 1.0) was adjusted to 7.0 using 1.0 N
HCl and 1.0 N NaOH. Neutralization was performed so that the
number of hydrogen ions became equal to that of hydroxide ions in
the CCFS, in order to rule out the effect of organic acids. Antimicrobial
activity of the neutralized extracellular extracts was tested against
S. aureus in a 96-well microplate, incubated at 37C for 20 hours.13
Antimicrobial activity of neutralized and protease-treated CCFS
Supernatants of selected LAB strain (OD 1.0) were neutralized to pH
7.0 and ﬁlter sterilized using a 0.22 mm membrane ﬁlter. Trypsin
(Sigma-Aldrich, Missouri, USA) and proteinase K (Sigma-Aldrich)
were added to the CFS at a ﬁnal concentration of 1 mg/mL. The
mixture was incubated at 37C for 1 hour. Upon incubation, the
enzymes were heat-inactivated by boiling for 3 minutes.15 The
resulting enzyme-treated CFS was tested for antimicrobial activity
against S. aureus in a 96-well microplate at 37C for 20 hours.
Antimicrobial activity of precipitated protein fraction
Precipitated protein fractions of selected LAB strains were prepared
using the modiﬁed ammonium sulfate precipitation method. Su-
pernatants of LAB (OD 1.0) were adjusted to pH 7 and ﬁltersterilized. Protein fraction was precipitated at 40% ammonium
sulfate saturation. The mixture was incubated at 4C for 24 hours
with continuous stirring. The precipitated supernatant was
centrifuged at 8590g for 1 hour at 4C, and the collected precipitate
was resuspended in 20 mL of 0.05 M sodium phosphate buffer, pH
7.0, prior to ﬁlter sterilization. The obtained protein fractions were
subjected to antimicrobial activity assay against S. aureus.16
Determination of protein content
Protein concentrations in the extracellular extracts of LAB were
determined using the Bradford method.17 First, 100 mL of the
sample was mixed with 100 mL of distilled water and 800 mL of
Bradford reagent. The mixture was allowed to stand at room tem-
perature for 5 minutes, and the absorbance of each sample was
measured at 596 nm. The standard curve of protein concentration
was constructed using a series of dilutions of the Bovine Serum
Albumin (BSA) protein standard stock solution.
Determination of hydrogen peroxide
A spectrophotometric method was used to determine the concen-
trations of hydrogen peroxide in extracellular extracts of selected
LAB, using o-dianisidine horseradish peroxidase.18 A standard curve
of hydrogen peroxide was prepared freshly, and absorbance was
measured at 430 nm.
Determination of organic acids
Concentrations of lactic acid and acetic acid in extracellular extracts
of selected LAB were determined using high-performance liquid
chromatography (HPLC). The HPLC system (Shimadzu, Nakagyo-ku,
Kyoto, Japan) consisted of an Aminex-HPX 87H column
(300  7.8 mm2; Bio-Rad, Hercules, CA, USA), and the temperature
of the column was maintained at 35C. An aliquot (20 mL) of the
ﬁltered samples was injected into the HPLC equipped with a UV
absorbance detector (Shimadzu) set at 215 nm. Degassed 0.004 M
H2SO4was used as themobile phase at a ﬂow rate of 0.6mL/minute.
HPLC-grade acetic acid and lactic acid (Sigma, Buchs, St. Gallen,
Switzerland) were used as standards.19
Determination of diacetyl
A colorimetric reaction method, using creatine and a-naphthol in
an alkaline medium, was employed to determine the concentra-
tions of diacetyl in the extracellular extracts of selected LAB. The
standard curve was prepared using fresh diacetyl (Merck, Hohen-
brunn, Germany), and absorbance was measured at 525 nm. The
diacetyl and the solution containing 3% NaOH and 3.5% a-naphthol
were stored with light preservation.19
Quantitative in vitro bioﬁlm formation of S. aureus
The S. aureus strainwas grown in tryptic soy broth (TSB) at 37C for
20 hours. The culture was standardized to an optical density
(600 nm) of 0.300  0.015 in TSB supplemented with 2% glucose
(w/v) to maximize ica operon induction.20 The bioﬁlm was evalu-
ated with a crystal violet assay using 1% crystal violet solution and
33% acetic acid. Upon incubation, the absorbance was measured at
596 nm.21
Statistical analysis
Data were analyzed using SPSS version 19.0 (IBM, New York, NY,
USA). A one-way analysis of variance was performed to study
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measure analysis of variance was used for time-based experi-
ments. The level of signiﬁcance was set at a ¼ 0.05. Data means
were compared by Tukey’s test. All experimental results were
expressed as mean values obtained from three replicates (n ¼ 3),
unless stated otherwise.
Results
Screening of LAB and biﬁdobacteria for antimicrobial activity
Antimicrobial activities of LAB and biﬁdobacteria categorized ac-
cording to their sources of origins were determined by measuring
the growth inhibition percentage of S. aureus cultured in the
presence of extracellular extracts of LAB and biﬁdobacteria in
relation to the control (Figure S1 in the supplementary material
online). All 87 strains of LAB and three strains of biﬁdobacteriawere
able to exhibit antimicrobial activity against the test organism, with
growth inhibition recorded ranging from 0.5% to 34.2%.
Higher percentages of growth inhibition (p < 0.05) were
demonstrated by ﬁve different strains of LAB from ﬁve different
categories, namely, Lactobacillus bulgaricus FTDC 8611 (A30) from
the dairy products category, Weissella cibaria BD 1514h (B7) from
the vegetable category, Lactobacillus fermentum BD 1512n (C5) from
the fruit category, L. fermentum BD 8913f (D10) from the meat
products category, and Lactobacillus casei BD 1511a (E10) from the
fermented food products category. Antimicrobial activities of these
strains were evaluated by imposing different treatments on the
extracellular extracts, while L. bulgaricus FTDC 8611 (A30), which
exhibited a higher percentage of inhibition (p < 0.05) than other
selected strains, was chosen for S. aureus bioﬁlm inhibition analysis.
Effects of different treatments on the antimicrobial activity of
LAB extracellular extracts (CFS)
Antimicrobial activities of the ﬁve selected LAB supernatants were
tested with different treatments imposed on the extracts.
Neutralization of the LAB supernatants resulted in a drastic
reduction (p < 0.05) in the percentage of S. aureus growth inhibi-
tion as compared to the non-neutralized CFS (Figure 1). Among all
strains, L. bulgaricus FTDC 8611 (A30) showed a higher drop
(approximately 75% reduction; p < 0.05) in growth inhibition after
the CFS was neutralized.
The neutralized and protease (proteinase K and trypsin)-treated
LAB supernatants of all selected strains exhibited poorer growth
inhibition (p < 0.05) of S. aureus than the untreated CFS (Figure 1).
Among the selected strains, both W. cibaria BD 1514h (B7) and
L. fermentum BD 8913f (D10) showed poorer growth inhibition
(p < 0.05), as compared to their neutralized CFS.
In this study, S. aureus growth inhibition by the selected ﬁve
protein-precipitated LAB supernatants was signiﬁcantly higher
(p < 0.05) than the growth inhibition by neutralized CFS and
protease-treated CFS (Figure 2). These crude protein fractions
signiﬁcantly inhibited (p < 0.05) the growth of test microorgan-
isms, with the percentage of inhibition ranging from 16.39% to
24.89%. However, this growth inhibition, when compared with the
inhibition caused by nontreated CFS, was still signiﬁcantly poor
(p < 0.05).
Characterization of LAB extracellular extracts
Supernatants of the ﬁve selected LAB strains were characterized to
determine the amount of antimicrobial agents present, including
lactic acid, acetic acid, hydrogen peroxide, diacetyl, and protein
(Tables 2 and 3).Generally, the amount of lactic acid produced by the LAB strains
was higher than that of acetic acid present in the extracellular ex-
tracts. Lactic acid comprised 69.39e73.45% of the total acids pro-
duced, whereas acetic acid comprised 28.57e30.61% (Table 2).
Based on the data, L. casei BD 1511a (E10) produced a large amount
(p < 0.05) of lactic acid compared to W. cibaria BD 1514h (B7),
which was 11.11% higher. The strain L. bulgaricus FTDC 8611 (A30)
was able to produce a higher concentration (p< 0.05) of acetic acid.
The total amount of acids produced by the LAB strains was higher
(p < 0.05) in the extracellular extracts of L. bulgaricus FTDC 8611
(A30) and L. fermentum BD 8913f (D10), with a total concentration
of 0.049 mmol/mL. Data also demonstrated that the pH in the MRS
growth medium of the ﬁve selected LAB strains was reduced
signiﬁcantly (p < 0.05) to approximately 4.0 upon incubation for
20 hours at 37C.
All the strains of LAB tested produced hydrogen peroxide, at
concentrations ranging between 0.003 mg/mL and 0.007mg/mL, in
the extracellular extracts (Table 3). Both L. fermentum BD 8913f
(D10) and L. fermentum BD 1512n (C5) produced signiﬁcantly large
amounts (p< 0.05) of hydrogen peroxide, which were, respectively,
57.14% and 50.00% higher than the amount produced by L. casei BD
1511a (E10).
Results showed that ﬁve selected LAB strains produced a
detectable amount of diacetyl but at a minimal concentration
(Table 3). The varying concentrations of diacetyl estimated from
these strains of LAB ranged from 0.171 ng/mL to 4.419 ng/mL in the
extracellular extracts.
Based on the data, the LAB strains studied produced varying
concentrations of protein, ranging from 0.119 mg/mL to 0.219 mg/
mL, in the extracellular extracts (Table 3). Among all the strains,
higher amounts (p < 0.05) of protein were produced by the strain
L. fermentum BD 1512n (C5), whereas a lower protein content
(p < 0.05) was observed in the extracellular extracts of L. bulgaricus
FTDC 8611 (A30).
Quantitative in vitro bioﬁlm formation of S. aureus and its
inhibition by extracellular extracts of LAB
As observed during the study, the control S. aureus was able to
produce a bioﬁlm, but the bioﬁlm took approximately 24 hours to
establish itself prior to reaching a state of dynamic equilibrium
(Figure 2). The highest absorbance measurement (OD596nm) recor-
ded for the bioﬁlm of the control was 1.0 at 24 hours prior to when
the bioﬁlm degraded to OD 0.06 at 36 hours and 48 hours. After
48 hours, an increase in absorbance suggested that the staphylo-
coccal bioﬁlm was reformed.
The growth of the bioﬁlm in the control throughout the
60 hours was signiﬁcantly higher (p< 0.05) than that in the sample.
The sample where S. aureus was incubated with the extracellular
extracts of L. bulgaricus FTDC 8611 (A30) showed relatively no
growth of the bioﬁlm, in which the absorbance (OD) measured was
near to 0.01 for up to 48 hours. After 48 hours, an increase in OD to
0.3 was observed, indicating that the bioﬁlm started to grow
(Figure 2). This phenomenon suggested that the extracellular
extract used was able to inhibit the formation of the bioﬁlm for up
to 48 hours. For a clearer illustration, the crystal violet bounded to
the bioﬁlm of the control and the sample in the microplate wells is
shown in Figure 3.
Discussion
LAB has been receiving signiﬁcant attention lately due to their
ability to exhibit an antagonistic effect on closely related bacteria
and many other food-borne and dermatological pathogens.7,22 In
this study, the extracellular extracts (CFS) of 90 strains of LAB and
Figure 1 Effects of non-neutralized CFS, neutralized CFS, neutralized and protease-treated CFS, and neutralized and protein-precipitated CFS on the growth inhibition of Staph-
ylococcus aureus. Values are expressed in percentage of growth inhibition in relation to the control. Error bars represent standard errors of means (n ¼ 3). aec Means in the CFS of
same treatment from ﬁve tested strains, with different superscripted lowercase letters are signiﬁcantly different (p < 0.05). AeD Means in the same strain among CFS of different
treatment, with different superscripted uppercase letters are signiﬁcantly different (p < 0.05). CFS ¼ cell-free supernatant.
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was proven in a previous study that the extracellular fraction
contained more inhibitives than the intracellular extracts.7
Five LAB strains, which showed a higher percentage of growth
inhibition in screening, namely, L. bulgaricus FTDC 8611 (A30),
W. cibaria BD 1514h (B7), L. fermentum BD 1512n (C5), L. fermentum
BD 8913f (D10), and L. casei BD 1511a (E10), were selected for
detailed studies. The primary antimicrobial effect exerted by LAB is
due to the production of organic acids, which reduces the pH of the
immediate environment, rendering it unsuitable for the growth of a
broad range of Gram-positive bacteria.13 From the results (Figure 1)
obtained, the deleterious effect of LAB on S. aureus was mainly dueFigure 2 Absorbance measurement (OD596) of the Staphylococcus aureus bioﬁlm
growth in the presence of Lactobacillus bulgaricus FTDC 8611 extracellular extracts
(sample) and nonfermented MRS broth (control) up to 60 hours, with 12 hours of
interval. Results are expressed as mean  standard error (n ¼ 3). Growth of the bioﬁlm
of the control is signiﬁcantly different from that of the sample, indicated by an asterisk
(p < 0.05). OD ¼ optical density; MRS ¼ De ManeRogosaeSharpe.to the production of organic acids, as neutralization of CFS resulted
in more than 50% drop in the percentage of inhibition from the
initial level. Upon fermentation, the pH of the CFS was reduced to
almost 4.0 for all strains (Table 2), which was unfavorable for the
growth of S. aureus, as its survival requires the pH to be in the range
4.5e9.3.23 In addition, the lipophilic and undissociated nature of
lactic and acetic acids allow the molecules to exhibit antibacterial
action through the penetration of bacterial membrane. The higher
pH environment in the bacterial cytoplasm will cause the acids to
dissociate and interrupt the transport process in the cells by dis-
rupting the proton motive force.24
Bioactive peptides and/or bacteriocins are important antimi-
crobial metabolites produced by LAB, which are proteinaceous in
nature. Such compounds inhibit speciﬁc microorganisms, particu-
larly Gram-positive bacteria.8 In order to investigate whether the
antimicrobial compounds that inhibited the growth of S. aureus
were proteinaceous, the CFS of selected LAB was neutralized to
eliminate the effects of acids and treated with protease. Proteolytic
enzymes that degrade proteins present in the CFS would therefore
render the proteinaceous antimicrobial compounds ineffective in
exerting their bactericidal effect.22 Among the selected strains, the
CFS of two strains, W. cibaria BD 1514h (B7) and L. fermentum BD
8913f (D10), showed a signiﬁcant reduction (p < 0.05) in the
inhibitive action compared to the neutralized CFS (Figure 1). The
presence of proteinaceous antimicrobial compounds in these two
strains was conﬁrmed. In addition, the inhibitive action of the
precipitated protein fractions of all selected strains was postulated
to be a result of the concentration of bioactive peptide-like com-
pounds through the salting out method. Many bioactive peptides of
LAB were produced in small amounts; therefore, to effectively
evaluate the antimicrobial activities of such peptides, one crucial
step was to concentrate the CCFS with the ammonium sulfate
precipitation method, which was employed in this study.25 Bioac-
tive peptides including bacteriocins can easily form pores on the
cytoplasmic membrane of sensitive cells and disrupt nucleic acids,
subsequently leading to ion leakage, loss of proton motive force,
and ultimately cell death.26
Table 2 Concentration of organic acids produced by LAB in extracellular extracts and changes in pH of MRS broth prior to and upon fermentation for 20 hours at 37C.
Strain Organic acid concentration (mmol/mL) pH
Lactic acid Acetic acid Total acid 0 h 20 h
Lactobacillus bulgaricus FTDC 8611 (A30) 0.032  0.001cA 0.014  0.001bB 0.046  0.002c 5.33  0.03aA 4.09  0.04aB
Weissella cibaria BD 1514h (B7) 0.035  0.001abA 0.014  0.001bB 0.049  0.002a 5.25  0.01bA 4.09  0.02aB
Lactobacillus fermentum BD 1512n (C5) 0.036  0.001aA 0.013  0.001bB 0.049  0.002ab 5.08  0.02dA 4.00  0.01cB
Lactobacillus fermentum BD 8913f (D10) 0.034  0.001abcA 0.015  0.001aB 0.049  0.002a 5.19  0.01cA 4.02  0.01bcB
Lactobacillus casei BD 1511a (E10) 0.033  0.001bcA 0.014  0.001bB 0.047  0.002bc 5.31  0.02aA 4.06  0.01abB
Results are expressed as mean  standard deviation (n ¼ 3).
aed Different superscripted lowercase letters indicate that the quantities in the same column are signiﬁcantly different (p < 0.05).
A,B Different superscripted uppercase letters indicate that the quantities in the same row are signiﬁcantly different (p < 0.05).
LAB ¼ lactic acid bacteria; MRS ¼ De ManeRogosaeSharpe.
Table 3 Concentrations of hydrogen peroxide, diacetyl, and protein in the extra-
cellular extracts of lactic acid bacteria cultured in MRS broth for 20 hours at
37C.
Strain Concentration
Hydrogen
peroxide (mg/mL)
Diacetyl
(ng/mL)
Protein
(mg/mL)
Lactobacillus bulgaricus
FTDC 8611 (A30)
0.006  0.001ab 0.171  0.071c 0.203  0.012ab
Weissella cibaria BD
1514h (B7)
0.007  0.001a 4.419  0.444a 0.194  0.008abc
Lactobacillus fermentum
BD 1512n (C5)
0.003  0.001c 1.039  0.330c 0.198  0.022ab
Lactobacillus fermentum BD
8913f (D10)
0.004  0.001bc 4.217  0.512ab 0.119  0.001d
Lactobacillus casei BD
1511a (E10)
0.006  0.001a 1.349  0.731c 0.219  0.005a
Results are expressed as mean  standard deviation (n ¼ 3).
aed Different superscripted lowercase letters indicate that the quantities in the same
column are signiﬁcantly different (p < 0.05).
MRS ¼ De ManeRogosaeSharpe.
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compounds produced by LAB, namely organic acids, hydrogen
peroxide, and diacetyl, were strain dependent (Tables 2 and 3).
L. bulgaricus FTDC 8611 (A30), the strongest of all these strains,
produced a large amount (p < 0.05) of acetic acid and total acids
compared to other strains (Table 2). Such data correlated well with
the high percentage of inhibition exerted by this strain (Figure 1).Figure 3 Growth of the (A) bioﬁlm of the control and (B) bioﬁlm of the sample in the polysty
bound to the bioﬁlm of Staphylococcus aureus prior to being solubilized in acetic acid. The int
was better in the control (unfermented MRS broth) than in the sample (CFS of strain Lacto
Sharpe.The effect of acetic acid (pKa 4.74), although present in a small
amount, is more lethal than that of lactic acid because the con-
centration of undissociated acetic acid is two to four times that of
lactic acid at pH 4.0e4.6.27 The higher percentage (p < 0.05) of
inhibition exhibited by L. bulgaricus FTDC 8611 (A30) was postu-
lated to be a result of the synergistic effect between the overall
antimicrobial compounds produced. Two ormore inhibitory factors
would result in an inhibitory action greater than either of the
different factors (synergism).28 The antagonistic activity of diacetyl
occurs through the blocking of enzyme’s catalytic site responsible
for arginine utilization, rendering the cells incapable of synthesiz-
ing essential proteins.29 Hydrogen peroxide oxidizes targeted bac-
terial membrane via peroxidation, leaving the cells with increased
membrane permeability and denatured metabolic enzymes.9 The
inhibition effect of bacteriocins was also found to increase efﬁ-
ciently via synergism between organic acids and bacteriocins.7
Bioﬁlm formation is one of the ways S. aureus expresses its
pathogenesis through the colonization of infection sites.3 In the
current study, results (Figure 2) showed that S. aureus (control) was
able to form a bioﬁlm throughout the 60 hours of incubation.
Growth pattern of the bioﬁlm was in good agreement with the
results of a previous study, which suggested that the bioﬁlm
established itself in the ﬁrst 24 hours of incubation prior to
reaching a state of dynamic equilibrium.30 After 24 hours of incu-
bation, cyclical maturation and dispersal of the bioﬁlm took place
as the bioﬁlm reached a critical mass, eventually unable to sustain
the bacteria encased within the matrix. Bacteria on the outermost
layers of the bioﬁlmwould then dissociate from it, leading to betterrene microplate at 24 hours. The purple color stain on the well was due to crystal violet
ensity of purple color was higher in (A) than in (B), indicating that the growth of bioﬁlm
bacillus bulgaricus FTDC 8611). CFS ¼ cell-free supernatant; MRS ¼ De ManeRogosae
Y.Y. Hor, M.T. Liong / Dermatologica Sinica 32 (2014) 141e147 147availability of nutrients to stimulate further growth until the con-
dition became favorable for the bacteria to form the bioﬁlm again,
which occurred at 60 hours in this study.
Results of this study (Figure 2) successfully proved that LAB
extracts can inhibit the bioﬁlm formation of S. aureus; the growth of
bioﬁlm in the presence of L. bulgaricus FTDC 8611 (A30) CFS was
signiﬁcantly lower (p < 0.05) than that in the presence of a control.
Antimicrobial compounds in the CFS were believed to work syn-
ergistically to halt the growth of the pathogen and even cause death
in the cells, rendering the aggregation of cells to form the bioﬁlm
unsuccessful. Bacteriocins produced by LAB may alter the physical
and chemical conditions of the culture conditions, and thus
development of the bioﬁlm becomes unfavourable.31
In conclusion, results of the present study illustrated that LAB
have the ability to synthesize antimicrobial compounds that can
inhibit the growth of the pathogen S. aureus. The bioﬁlm formed by
S. aureus was successfully inhibited by the extracellular extracts of
LAB, proving that LAB can serve as a potential alternative in
dermatological applications.
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